Pharmacogenomics can identify polymorphisms in genes involved in drug pharmacokinetics
and pharmacodynamics determining differences in efficacy and safety and causing inter …

Modifications of the activity of Cytochrome 450 (CYP) enzymes by compounds in food might
impair medical treatments. These CYP-mediated food–drug interactions (FDI) play a major …

Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain
immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research …

Background Whole genome sequencing is increasingly used in healthcare, particularly for
diagnostics. However, its clinically multifaceted potential for individually customised …

Background Multidrug regimens can increase the risk of drug–drug interactions at the level
of albumin binding especially for drugs with narrow therapeutic windows such as …

The gene polymorphisms of ABCB1, EPHX1, and SCN1A were found to influence
carbamazepine (CBZ) metabolism and resistance in epilepsy patients, but the relevance …

Pharmacogenetics is defined as the study of genetic variability in drug response, either in
terms of efficacy or safety. Many drug hypersensitivity pharmacogenetic associations have …

В обзоре систематизирована и представлена актуальная информация, касающаяся
фармакокинетики и фармакогенетики карбамазепина, а также наиболее …

Epilepsy is a neurological disease that requires long-term drug therapy. Carbamazepine
(CBZ) is a drug that is effective in partial seizures, including complex partial seizures, and …

Особенности фармакогенетики карбамазепина и наиболее частые нежелат Page 1 255
Лицензия CC BY-NC-ND 4.0 © Коллектив авторов, 2022 Обзоры по клинической …